US Biotech Share Sales Deliver Biggest First Week Since 2021

Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology fundraising after turbulence in the sector last year.

Aided by a rebound in share prices across the sector, a burst of acquisitions by big drugmakers and receding concerns about the regulatory backdrop, biotechs and pharmaceutical companies raised $2.5 billion from sales of new shares, including in Aktis Oncology Inc.’s initial public offering, in the first week of January, according to data compiled by Bloomberg. That marks the busiest start to the year since 2021, the data show.